This proposal describes a comprehensive program involving synthetic, mechanistic, biological, and computer modelling studies directed at the elucidation of the mode of action of demonstrated and of potential cancer chemotherapeutic agents, at the rational design and development of new classes of antitumor agents, and at the development of fundamentally new methodology and strategies for the synthesis of such agents. Five projects are proposed for investigation. A major continuation study will be directed at neocarzinostatin chromophore, the recently identified, structurally unprecedented, """"""""biologically active subunit of neocarzinostatin (NCS), a drug used in human cancer chemotherapy. Efforts will focus on determining the molecular basis for the antitumor activity of NCS, on establishing the basis for its DNA cleavage selectivity. on the utilization of this information in the rational design of new antitumor agents, and on the synthesis of simplified analogues and biological probes needed in support of these studies. A second major project is focussed on dynemicin A (Dyn A), an exciting new chemotherapeutic lead exhibiting significant in vitro and in vivo antitumor activity. Attention will be directed at the mechanism of activation of Dyn A, at the rational design and development of new Dyn A analogues, at the structural basis for its DNA lesion selectivity, and at an examination of a potentially biomimetic approach to its unprecedented - structure. A third project is directed at the development of fundamentally new classes of DNA-cleaving agents and potential cancer chemotherapeutics that are designed to function by the transition metal, photochemical, and torsional induction of diradical formation. A fourth major effort is focussed on taxol, a compound whose recent, impressive clinical performance is likely to result in' its imminent approval for use in cancer chemotherapy. This study is directed at the development of practical approaches to taxol analogues and at the elucidation of the structural requirements for taxol's activity. A final project entails completion of studies on the synthesis of aplysiatoxin. Overall, this research program is expected to be of significant value in chemistry, biology, and medicine.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA031845-15
Application #
2088246
Study Section
Medicinal Chemistry Study Section (MCHA)
Project Start
1981-07-01
Project End
1996-03-31
Budget Start
1995-04-01
Budget End
1996-03-31
Support Year
15
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Stanford University
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
800771545
City
Stanford
State
CA
Country
United States
Zip Code
94305
McKinlay, Colin J; Benner, Nancy L; Haabeth, Ole A et al. (2018) Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters. Proc Natl Acad Sci U S A 115:E5859-E5866
Fernandes-Cunha, Gabriella M; McKinlay, Colin J; Vargas, Jessica R et al. (2018) Delivery of Inorganic Polyphosphate into Cells Using Amphipathic Oligocarbonate Transporters. ACS Cent Sci 4:1394-1402
Yang, Hao; Staveness, Daryl; Ryckbosch, Steven M et al. (2018) REDOR NMR Reveals Multiple Conformers for a Protein Kinase C Ligand in a Membrane Environment. ACS Cent Sci 4:89-96
Haabeth, Ole A W; Blake, Timothy R; McKinlay, Colin J et al. (2018) mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice. Proc Natl Acad Sci U S A 115:E9153-E9161
Khan, Tapan K; Wender, Paul A; Alkon, Daniel L (2018) Bryostatin and its synthetic analog, picolog rescue dermal fibroblasts from prolonged stress and contribute to survival and rejuvenation of human skin equivalents. J Cell Physiol 233:1523-1534
Marsden, Matthew D; Wu, Xiaomeng; Navab, Sara M et al. (2018) Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents. Virology 520:83-93
Albert, Brice J; Niu, Austin; Ramani, Rashmi et al. (2017) Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation. Sci Rep 7:7456
Ryckbosch, Steven M; Wender, Paul A; Pande, Vijay S (2017) Molecular dynamics simulations reveal ligand-controlled positioning of a peripheral protein complex in membranes. Nat Commun 8:6
McKinlay, Colin J; Vargas, Jessica R; Blake, Timothy R et al. (2017) Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals. Proc Natl Acad Sci U S A 114:E448-E456
Wender, Paul A; Hardman, Clayton T; Ho, Stephen et al. (2017) Scalable synthesis of bryostatin 1 and analogs, adjuvant leads against latent HIV. Science 358:218-223

Showing the most recent 10 out of 90 publications